Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
Posted on: Monday, 23 March 2009, 07:30 CDT
SAN MATEO‚ Calif.‚
About Relaxin
Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure.
About Corthera
Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin. For more information, visit www.corthera.com.
Contact: Andreas Marathovouniotis or David Schull Russo Partners 212.845.4235 andreas.marathis@russopartnersllc.com david.schull@russopartnersllc.comSOURCE Corthera
Source: PR Newswire
Related Articles
- Clinical Center of Serbia, Institute for Cardiovascular Diseases Treats First Patient in Trial of Pioneering Stem Cell-Derived Therapy for Heart Failure
- Recognizing Signs, Symptoms Of Acute HF
- Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
- Amorcyte Completes Phase I Trial of Stem Cell Therapy for Acute Myocardial Infarction
- Hawthorn Extract May Help Heart Failure
- Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
- Tufts-New England Medical Center Named an Abiomed Center of Excellence for Commitment to Heart Recovery for Acute Patients
- Positive Results From CVBT's Phase I No-Option Heart Disease Clinical Trial Will Be Presented at the American Heart Association's Annual Meeting
- Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
- Boise-Based Primary Health Inc., Sans Clinics, Looks Forward to Growth
 |
 |
User Comments (0)
RSS Feeds